» Articles » PMID: 19432822

Lipophilic but Not Hydrophilic Statins Selectively Induce Cell Death in Gynaecological Cancers Expressing High Levels of HMGCoA Reductase

Overview
Journal J Cell Mol Med
Date 2009 May 13
PMID 19432822
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Recent reports have suggested that statins induce cell death in certain epithelial cancers and that patients taking statins to reduce cholesterol levels possess lower cancer incidence. However, little is known about the mechanisms of action of different statins or the effects of these statins in gynaecological malignancies. The apoptotic potential of two lipophilic statins (lovastatin and simvastatin) and one hydrophilic statin (pravastatin) was assessed in cancer cell lines (ovarian, endometrial and cervical) and primary cultured cancerous and normal tissues. Cell viability was studied by MTS assays and apoptosis was confirmed by Western blotting of PARP and flow cytometry. The expressions of key apoptotic cascade proteins were analysed. Our results demonstrate that both lovastatin and simvastatin, but not pravastatin, selectively induced cell death in dose- and time-dependent manner in ovarian, endometrial and cervical cancers. Little or no toxicity was observed with any statin on normal cells. Lipophilic statins induced activation of caspase-8 and -9; BID cleavage, cytochrome C release and PARP cleavage. Statin-sensitive cancers expressed high levels of HMG-CoA reductase compared with resistant cultures. The effect of lipophilic statins was dependent on inhibition of enzymatic activity of HMG-CoA reductase since mevalonate pre-incubation almost completely abrogated the apoptotic effect. Moreover, the apoptotic effect involved the inhibition of synthesis of geranylgeranyl pyrophosphate rather than farnesyl pyrophosphate. In conclusion, lipophilic but not hydrophilic statins induce cell death through activation of extrinsic and intrinsic apoptotic cascades in cancerous cells from the human female genital tract, which express high levels of HMG-CoA reductase. These results promote further investigation in the use of lipophilic statins as anticancer agents in gynaecological malignancies.

Citing Articles

SATB1 in cancer progression and metastasis: mechanisms and therapeutic potential.

Bai J, Yang G, Yu Q, Chi Q, Zeng X, Qi W Front Oncol. 2025; 15:1535929.

PMID: 40071088 PMC: 11893431. DOI: 10.3389/fonc.2025.1535929.


Current Approaches and Innovations in Managing Preeclampsia: Highlighting Maternal Health Disparities.

Dickerson A, Joseph C, Kashfi K J Clin Med. 2025; 14(4).

PMID: 40004721 PMC: 11856135. DOI: 10.3390/jcm14041190.


Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing.

Mikhael S, Daoud G Cancer Med. 2025; 14(4):e70681.

PMID: 39969135 PMC: 11837049. DOI: 10.1002/cam4.70681.


Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.

Tarar Z, Farooq U, Inayat F, Basida S, Ibrahim F, Gandhi M World J Exp Med. 2024; 14(4):98543.

PMID: 39713070 PMC: 11551700. DOI: 10.5493/wjem.v14.i4.98543.


Nanomedicine marvels: crafting the future of cancer therapy with innovative statin nano-formulation strategies.

Karimi Jirandehi A, Asgari R, Shahbaz S, Rezaei N Nanoscale Adv. 2024; .

PMID: 39478996 PMC: 11515941. DOI: 10.1039/d4na00808a.


References
1.
Kofler S, Schlichting C, Jankl S, Nickel T, Weis M . Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion. Atherosclerosis. 2007; 197(1):105-10. DOI: 10.1016/j.atherosclerosis.2007.08.005. View

2.
Turner N, Midgley L, ORegan D, Porter K . Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007; 50(4):458-61. DOI: 10.1097/FJC.0b013e318123767f. View

3.
Hamelin B, Turgeon J . Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998; 19(1):26-37. DOI: 10.1016/s0165-6147(97)01147-4. View

4.
Han Z, Wyche J . Lovastatin induces apoptosis in a metastatic ovarian tumour cell line. Cell Death Differ. 1996; 3(2):223-8. View

5.
Kusuhara H, Sugiyama Y . Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002; 78(1-3):43-54. DOI: 10.1016/s0168-3659(01)00480-1. View